Boston Scientific (BSX) to Release Earnings on Wednesday

Share on StockTwits

Boston Scientific (NYSE:BSX) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, April 24th. Analysts expect Boston Scientific to post earnings of $0.36 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.02. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.57 billion. During the same quarter in the previous year, the business earned $0.34 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. On average, analysts expect Boston Scientific to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Shares of NYSE:BSX opened at $35.11 on Monday. Boston Scientific has a 1 year low of $27.91 and a 1 year high of $41.00. The stock has a market cap of $48.82 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 2.06 and a beta of 0.87. The company has a current ratio of 0.76, a quick ratio of 0.54 and a debt-to-equity ratio of 0.55.

In other news, CFO Daniel J. Brennan sold 22,438 shares of the business’s stock in a transaction that occurred on Thursday, February 14th. The stock was sold at an average price of $39.57, for a total value of $887,871.66. Following the sale, the chief financial officer now directly owns 279,183 shares of the company’s stock, valued at approximately $11,047,271.31. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 64,223 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.84, for a total value of $2,622,867.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 342,352 shares of company stock worth $13,701,434. Insiders own 0.66% of the company’s stock.

A number of research analysts recently issued reports on BSX shares. Zacks Investment Research downgraded Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, December 31st. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Tuesday, January 8th. Guggenheim restated a “buy” rating and set a $48.00 price target on shares of Boston Scientific in a report on Friday, February 8th. SunTrust Banks restated a “buy” rating and set a $47.00 price target on shares of Boston Scientific in a report on Friday, February 8th. Finally, Canaccord Genuity restated a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a report on Monday, February 11th. Three research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.72.

WARNING: This piece of content was originally published by Highlight Press and is the property of of Highlight Press. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://highlightpress.com/2019/04/22/boston-scientific-bsx-to-release-earnings-on-wednesday.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Reverse Stock Split

Earnings History for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.